Ultima-Tesamorelin, 5 mg

Ultima-Tesamorelin 5 mg contains tesamorelin, a synthetic growth hormone-releasing hormone (GHRH) analogue. It stimulates the pituitary gland to increase growth hormone release and is particularly associated with fat metabolism, body composition, visceral-fat reduction, lean-mass support, and growth-hormone signaling.

How it works

Tesamorelin binds to GHRH receptors in the pituitary gland, stimulating the natural release of growth hormone. Increased GH activity can subsequently influence the IGF-1 pathway, which plays an important role in metabolism, tissue development, and body composition.

Tesamorelin is particularly recognized for its effects on visceral adipose tissue, making it especially relevant to body-composition and fat-management applications.

Proper Use and Dosage

The listed presentation contains 5 mg (5,000 mcg) of tesamorelin.

The FDA-approved tesamorelin formulation is administered once daily. For the currently approved formulation, the labeled adult dosage is 1.4 mg once daily, administered subcutaneously.

For a 5 mg presentation:

• 500 mcg = 10 administrations
• 1 mg = 5 administrations
• 1.25 mg = 4 administrations
• 1.4 mg = approximately 3.5 administrations
• 2.5 mg = 2 administrations
• 5 mg = 1 full vial

For body-composition applications, tesamorelin is generally associated with growth-hormone support and visceral-fat management.

Benefits

Ultima-Tesamorelin is particularly suited to applications involving body composition, visceral-fat reduction, metabolic support, and growth-hormone signaling.

Key benefits and areas of interest include:

• Stimulates endogenous growth hormone release
• Supports GH–IGF-1 pathway activity
• Promotes visceral-fat reduction
• Supports improved body composition
• Supports fat-metabolism pathways
• Helps maintain lean body mass
• Supports metabolic health
• May complement physique-focused programs
• Supports recovery and tissue-maintenance pathways
• Convenient 5 mg presentation

Its strongest distinguishing feature is its focus on visceral adipose tissue, making tesamorelin particularly attractive for body-composition-focused applications.

Side Effects

Possible effects may include injection-site reactions, redness, itching, headache, joint discomfort, muscle pain, swelling, and changes in blood glucose or IGF-1 levels. Increased growth-hormone activity may also contribute to fluid retention or tingling sensations in some individuals.